SLAYEN HOWARD T sold $2.2M of AEHR

SLAYEN HOWARD T (Director) sold 20,000 shares of AEHR TEST SYSTEMS (AEHR) at $108.30 ($2.17M total) on 2026-08-04.

Original reporting
SEC EDGAR · SLAYEN HOWARD T
Published Aug 5, 2026, 1:16 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 5, 2026, 2:07 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$AEHR
Neutral
medium confidence
Mentioned
$AEHR
Relevance
6/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$AEHRNeutralLow
01

Why it matters

A director’s open-market sale of $2.17M is new information for traders monitoring insider behavior, but it does not include any guidance, deal, regulatory action, or operational update.

02

Market read

Traders may briefly reassess sentiment toward AEHR based on the disclosed insider sale size and timing, but the filing lacks fundamental catalysts.

03

What to watch

Insider sales can be misread without context such as prior holdings, compensation structure, and whether other insiders are selling or buying around the same period.

Relevance 6/10Novelty 3/10Timing: filed 2026-08-04 after-hours; sale dated 2026-08-04

Background

The article is a SEC Form 4 insider transaction disclosure for AEHR Test Systems.

Company-level read

Ticker impact

$AEHRNeutralMedium confidence
Context

AEHR director Slayen Howard T sold 20,000 shares in an open-market transaction at $108.2961 on 2026-08-04, totaling $2.17M.

Expected impact

Likely limited, short-lived sentiment impact; watch for follow-on selling or unusual volume around the filing date.

Evidence & confidence

The filing is a Form 4 insider transaction with a specific sale price and size, but it provides no new company-specific operational or financial information.

Market effects

No direct sector read-through; this is company-specific insider activity.

None indicated.

None indicated.

Counterpoint

The sale may be routine liquidity or tax-related, especially since the filing notes no 10b5-1 plan, so it could reflect personal timing rather than a view on AEHR.

Key entities

  • AEHR Test Systems

    Company whose director insider sale is disclosed via Form 4.

  • Slayen Howard T

    Director who sold 20,000 shares at $108.2961 on 2026-08-04.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$AEHRHighAI 9/10

Aehr Test Systems (AEHR) (Q1 2027) Earnings Call Highlights: Record Revenue, Raised

Aehr Test Systems (AEHR) reported record Q1 2027 revenue of $33M and raised annual guidance to $150M. CEO Gayn Erickson highlighted a potential large burn-in opportunity, estimating $35M-$70M in revenue per million units shipped. The company expects sequential growth in remaining quarters, with Q4 potentially the highest. Management confirmed they are not supply-constrained and can ship more than guided. Silicon carbide revenue was about $10M in fiscal 2026, with expectations for growth in 2027.

$AEHRHighAI 9/10

AEHR Stock Surges After Massive AI-Driven Earnings Beat

Aehr Test Systems (AEHR) stock rose 26.6% after reporting Q1 FY27 revenue of $33M, up 300% year-over-year and 75% quarter-over-quarter. Adjusted EPS was $0.28, beating estimates. The company raised FY27 revenue guidance to $150M, citing strong demand for AI and power semiconductor testing.

$AEHRHighAI 9/10

Aehr Stock Jumps 16% After Bookings Hit $46.7 Million

Aehr Test Systems (AEHR) shares rose 16.38% premarket after its Q1 revenue tripled to $33.0M, beating estimates. The company raised its full-year outlook to $150M, citing strong bookings and backlog growth. CEO Gayn Erickson highlighted a major AI customer opportunity. According to GuruFocus, there are 6 warning signs with AEHR.

$AEHRHighAI 8/10

Why is Aehr Test Systems stock surging today?

Aehr Test Systems (AEHR) stock surged 18.8% in pre-market trading after reporting record Q1 2027 revenue of $33.0M, up 200% YoY, and raising full-year revenue outlook to $150M. Non-GAAP net income was $9.4M, or $0.28 per share, exceeding analyst estimates. The company cited strong demand for AI semiconductor test solutions and a book-to-bill ratio of 1.4.

$AEHRMed

Aehr stock jumps on beat and raise amid AI demand

Aehr Test Systems (AEHR) shares rose 15% after reporting Q1 revenue of $33M, up 200% YoY, and raising its FY2027 outlook to $150M. The company cited strong demand for its semiconductor testing systems used in AI chips. CEO Gayn Erickson noted a conservative approach to the revised target. Bookings were $46.7M with a book-to-bill ratio of 1.4.